Myriam El Gaaloul

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.

D. Sonnichsen, R. Abbas, S. Chalon, 2012, Clinical therapeutics.

Re-orienting anti-malarial drug development to better serve pregnant women

W. Kaszubska, Myriam El Gaaloul, B. Tornesi, 2022, Malaria journal.

First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection

T. Hammond, J. Möhrle, U. Lorch, 2020, British journal of clinical pharmacology.

Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs

A. Rosanas-Urgell, K. Barnes, A. Kümmel, 2022, The American journal of tropical medicine and hygiene.

Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement

G. Aldrovandi, M. Boffito, J. Kinuthia, 2020, Clinical pharmacology and therapeutics.

Evaluation of the safety and efficacy of dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH project)

C. Menéndez, B. Lell, J. Mischlinger, 2021, BMJ Open.

Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers

G. Ferber, U. Lorch, J. Täubel, 2021, British journal of clinical pharmacology.

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study

A. Rosanas-Urgell, Mohammed H. Cherkaoui-Rbati, Iñigo Angulo-Barturen, 2021, The American journal of tropical medicine and hygiene.

Re-orienting anti-malarial drug development to better serve pregnant women

W. Kaszubska, Myriam El Gaaloul, B. Tornesi, 2022, Malaria journal.

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.

H. Tinto, B. Ogutu, C. Risterucci, 2023, The Lancet. Infectious diseases.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults

J. McCarthy, K. Barnes, C. Engwerda, 2021, Antimicrobial agents and chemotherapy.